Market Launch of ReNcell

ReNeuron Group plc
20 November 2006

ReNeuron and Millipore announce market launch of ReNcell(TM) neural stem cell
lines


Guildford, UK, 20 November 2006:  ReNeuron Group plc (LSE: RENE.L) and Millipore
Corporation (NYSE: MIL), announce the market launch of ReNeuron's patented
ReNcell(TM) neural stem cell lines for non-therapeutic applications.  These
products are the only immortalised human somatic neural stem cell lines on the
market today.


The launch follows the establishment of a manufacturing and distribution
agreement signed by ReNeuron and Chemicon International, Inc., now part of
Millipore, earlier this year.  Under the terms of this multi-year agreement,
Millipore will exclusively manufacture and supply ReNeuron's ReNcell(TM) CX and
ReNCell(TM) VM cell lines and cell media to the worldwide stem cell research
community within academia and the pharmaceutical industry.  ReNeuron will
receive royalty payments on cell line and media sales made by Millipore.


The ReNcell(TM) lines have been specifically generated by ReNeuron for
application as models for regenerative medicine. The cell lines and media are
available either individually or as a kit and represent a convenient solution
for scientists needing reproducible results with neurons easily derived from
human cells. The cell lines are particularly useful in drug discovery
applications, where the development of these pathways can be monitored during
drug screening.


Further information concerning the ReNcell(TM) neural cell lines may be found by
contacting Millipore Tech Service at [phone] (or 1 800 548 7853 in the
US), or by visiting www.millipore.com.


Michael Hunt, Chief Executive Officer of ReNeuron, said:


'We have been encouraged by the level of enquiries from potential customers for
the ReNcell(TM) lines leading up to market launch, and we look forward to our
continuing collaboration with Millipore as the scientific research and
commercial potential of these cell lines is realised in the months and years
ahead.'


Michelle Greene, Millipore Marketing Director, said:


'The ReNcell(TM) neural cell lines have the ability to readily differentiate
into neural cell types and will replicate indefinitely. The cells display the
same marker patterns as normal cells and are able to grow and remain stable,
even after prolonged culturing.  Neurons derived from these cells show the
physiological properties of mature neurons, a valuable characteristic when
validating research results using these ReNcell(TM) products.'



Enquiries:


ReNeuron                                                 Tel: [phone]
Michael Hunt, Chief Executive Officer
John Sinden, Chief Scientific Officer


Financial Dynamics                                       Tel: [phone]
David Yates
Nicola Daley


Notes to Editors


About ReNeuron Group plc


ReNeuron is a leading, UK-based adult stem cell therapy business.  The Group is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.


ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.


The Group's lead stem cell therapy, ReN001 for chronic stroke disability, is in
late pre-clinical development.  The Company plans to file for approval to
commence a Phase I clinical study in stroke by the end of 2006, with the study
commencing as soon as possible thereafter.   There are an estimated 50 million1
stroke survivors worldwide, approximately half of which are left with permanent
disabilities.  The healthcare costs of caring for these patients is estimated to
amount to $45 billion2 in the US alone.


ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell(TM) range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry.


ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.


Further information on ReNeuron and its products can be found at
www.reneuron.com.


 1. MOSES (Morbidity and mortality after stroke - Eprosartan vs nitrendipine for
    secondary prevention) study, Feb 2006
 2. American Heart Association, Reporting Standards for Carotid Artery
    Angioplasty and Stent Placement, (Stroke, 2004; 35:e112).


About Millipore Corporation


Millipore is a leading provider of products and services that improve
productivity in biopharmaceutical manufacturing and in clinical, analytical and
research laboratories. The Company is organized in two operating divisions. Its
Bioprocess Division helps enables pharmaceutical and biotechnology companies to
optimize their manufacturing productivity, ensure the quality of drugs, and
scale up the production of difficult-to-manufacture biologics.  Its Bioscience
division helps to optimize laboratory productivity and workflows.


Its products and enabling technologies that are used in the laboratory are
essential for the research and development of biologically based life science
therapeutics.  Millipore has a deep understanding of its customers' research and
manufacturing process needs, and offers reliable and innovative tools,
technologies and services.  The Company is part of the S&P 500 index and employs
approximately 5,800 employees in more than 47 offices worldwide.


For additional information on Millipore Corporation, please visit its website
at: www.millipore.com.


This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.




                      This information is provided by RNS
            The company news service from the London Stock Exchange